---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-118858"
form_type: "8-K/A"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:17:40.649247+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Collegium completes Ironshore acquisition; discloses Ironshore's $49.8M net loss for 2023 and $67.4M for H1 2024

## Summary
- Acquisition closed Sept 3, 2024; Ironshore's JORNAY PM (ADHD) product revenue $78.6M in 2023, $43.8M in H1 2024.
- Ironshore total assets $84.7M, total liabilities $442.3M, shareholders' deficit $(357.6)M at June 30, 2024.
- Ironshore notes payable (current + non-current) $149.8M at June 30, 2024; asset-backed lending $12.6M.
- Deferred royalty obligation $123.5M at June 30, 2024; warrant liability $8.3M; derivative liability $36.0M.
- Ironshore's net loss $(49.8)M in 2023 and $(67.4)M in H1 2024, with operating losses since inception.

## SEC filing metadata
- accession: 0001104659-24-118858
- form_type: 8-K/A
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465924118858/0001104659-24-118858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465924118858/tm2428082d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-118858
- JSON: https://secwatch.observer/filing/0001104659-24-118858.json
- Plain text: https://secwatch.observer/filing/0001104659-24-118858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.